Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Regulatory and reimbursement issues in treating patients with immune-mediated neuropathies.

Donofrio PD, Busis NA.

Neurology. 2002 Dec 24;59(12 Suppl 6):S41-5. Review.

PMID:
12499470
2.

[The rational immunotherapy with intravenous immunoglobulin in neurologic diseases].

Korsak J.

Pol Merkur Lekarski. 2011 Jun;30(180):430-4. Review. Polish.

PMID:
21751554
3.

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.

Gold R, Stangel M, Dalakas MC.

Nat Clin Pract Neurol. 2007 Jan;3(1):36-44. Review.

PMID:
17205073
4.

Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.

Dalakas MC.

J Neurol. 2006 Sep;253 Suppl 5:V25-32. Review. Erratum in: J Neurol. 2008 Feb;255(2):308.

PMID:
16998751
5.

[Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Stangel M, Gold R.

Nervenarzt. 2004 Aug;75(8):801-15. Review. German.

PMID:
15224177
6.

IVIG therapy in neurological disorders of childhood.

Archelos JJ, Fazekas F.

J Neurol. 2006 Sep;253 Suppl 5:V80-6. Review. Erratum in: J Neurol. 2008 Feb;255(2):308.

PMID:
16998760
7.

A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers.

Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA.

Ann Pharmacother. 2000 Mar;34(3):295-9.

PMID:
10917372
8.
9.

Intravenous immunoglobulin use for neurologic diseases.

Koski CL, Patterson JV.

J Infus Nurs. 2006 May-Jun;29(3 Suppl):S21-8. Review.

PMID:
16878852
10.

Advances in the use of IVIg in neurological disorders.

Hughes R.

J Neurol. 2008 Jul;255 Suppl 3:1-2. doi: 10.1007/s00415-008-3001-1. No abstract available.

PMID:
18685918
11.

Advances in the understanding of the mechanism of action of IVIg.

Hartung HP.

J Neurol. 2008 Jul;255 Suppl 3:3-6. doi: 10.1007/s00415-008-3002-0. Review.

PMID:
18685919
12.
13.
14.

Intravenous immunoglobulin in therapy of peripheral neuropathy.

Gorshtein A, Levy Y.

Clin Rev Allergy Immunol. 2005 Dec;29(3):271-9. Review.

PMID:
16391402
15.

Treatment of immune-mediated, dysimmune neuropathies.

Finsterer J.

Acta Neurol Scand. 2005 Aug;112(2):115-25. Review.

PMID:
16008538
16.

Unlabeled uses of intravenous immune globulin.

Leong H, Stachnik J, Bonk ME, Matuszewski KA.

Am J Health Syst Pharm. 2008 Oct 1;65(19):1815-24. doi: 10.2146/ajhp070582. Review.

PMID:
18796422
17.

The role of IVIg in autoimmune neuropathies: the latest evidence.

Hughes R.

J Neurol. 2008 Jul;255 Suppl 3:7-11. doi: 10.1007/s00415-008-3003-z. Review.

PMID:
18685920
18.

Off-label use reimbursement.

Cohen J, Wilson A, Faden L.

Food Drug Law J. 2009;64(2):391-403.

PMID:
19999289
19.

Intravenous immunoglobulin: striving for appropriate use.

Kumar A, Teuber SS, Gershwin ME.

Int Arch Allergy Immunol. 2006;140(3):185-98. Review.

PMID:
16682800
20.

[Current use of immunoglobulins in neurology].

Cursiefen S, Mäurer M.

Nervenarzt. 2008 Sep;79 Suppl 2:67-74; quiz 75-6. doi: 10.1007/s00115-008-2461-y. Review. German.

PMID:
18679643
Items per page

Supplemental Content

Support Center